• P2RX1 Drives Mitochondrial Apoptosis in Ph+ ALL via CaMKII–P

  2026-08-06

  Li et al. (2025) reveal that P2RX1 overexpression enhances mitochondrial apoptosis in Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) cells by disrupting calcium homeostasis and inhibiting PI3K/Akt signaling. These findings provide mechanistic insight into TKI resistance and highlight P2RX1 as a potential therapeutic target for overcoming poor prognosis in Ph+ ALL.

• Translational Leverage: Cy3 RNA Probe Innovation in Tumor mR

  2026-08-06

  Explore how the HyperScribe™ T7 High Yield Cy3 RNA Labeling Kit advances fluorescent RNA probe strategies for translational research, with mechanistic insight into T7 transcription, competitive context, and actionable guidance for in situ hybridization and tumor-selective mRNA delivery. This thought-leadership piece bridges next-generation probe synthesis with the therapeutic frontier, referencing cutting-edge evidence and integrating scenario-driven best practices.

• Recombinant Mouse Sonic Hedgehog: Advanced Uses in Patternin

  2026-08-05

  Recombinant Mouse Sonic Hedgehog (SHH) protein is transforming developmental biology with its precision in modeling limb, brain, and urogenital patterning. This article unpacks protocol enhancements, comparative research insights, and troubleshooting strategies to maximize experimental reliability and reproducibility in hedgehog signaling studies.

• Unlocking Apoptosis Insights: JC-1 Assays in Translational O

  2026-08-05

  This article offers a thought-leadership perspective on leveraging the JC-1 Mitochondrial Membrane Potential Assay Kit for advanced mitochondrial function analysis in oncology research. Integrating mechanistic insights with practical workflow guidance, it examines how ratiometric detection of mitochondrial membrane potential empowers translational scientists to dissect apoptosis and optimize combinatorial cancer therapies targeting mitochondrial integrity, including novel molecular glue strategies.

• Gastrin I (human): Precision Modulation in Intestinal Organo

  2026-08-04

  Explore the scientific impact of human Gastrin I peptide in advancing gastrointestinal physiology studies and the fine-tuning of gastric acid secretion pathway research using next-generation stem cell-derived intestinal organoids.

• LAG-3/TCR Proximity: Mechanisms of T Cell Suppression in Aut

  2026-08-04

  This study reveals that the spatial proximity between LAG-3 and the T cell receptor (TCR), rather than MHC class II binding alone, is critical for suppressing T cell activation and autoimmunity. The findings identify a new molecular mechanism for immune checkpoint regulation and demonstrate the therapeutic potential of bispecific antibodies targeting LAG-3/TCR proximity.

• ALDOB K87 Lactylation Drives Mitochondrial Fission in PH

  2026-08-03

  This study uncovers lysine-87 lactylation of aldolase B (ALDOB) as a pivotal regulatory event linking metabolic reprogramming to mitochondrial fission and pathological proliferation in pulmonary hypertension (PH). The findings highlight a lactate–ALDOB–DRP1 axis that exacerbates smooth muscle cell remodeling, suggesting new intervention targets for PH.

• HyperScribe Co-transcription mRNA Synthesis Kit Plus: Advanc

  2026-08-03

  Unlock translationally robust, ARCA-capped mRNA with the HyperScribe Co-transcription mRNA Synthesis Kit Plus. This guide bridges recent nanovaccine breakthroughs, practical workflow enhancements, and troubleshooting strategies for high-yield, polyadenylated mRNA production in advanced RNA vaccine and functional genomics research.

• VX-765 and VRT-043198: Selective Caspase-1 Inhibition in Adv

  2026-08-02

  Explore how VX-765, a potent caspase-1 inhibitor, unlocks new frontiers in inflammation and cell death research. This article uniquely integrates mechanistic insights, assay protocol guidance, and translational perspectives beyond current literature.

• JNK-IN-7: Selective JNK Inhibitor for Advanced Apoptosis Ass

  2026-08-01

  JNK-IN-7 empowers researchers with precise control over MAPK pathway interrogation, enabling highly specific apoptosis and innate immune signaling studies. Its covalent selectivity and robust solubility profile streamline experimental workflows, especially in dissecting c-Jun phosphorylation and Toll receptor signaling.

• Niclosamide in Translational Oncology: Mechanisms and Modern

  2026-07-31

  Explore the multifaceted role of Niclosamide as a STAT3 pathway inhibitor in cancer research. This article uniquely examines its mechanistic depth, comparative efficacy versus plant-based alternatives, and practical assay implications for translational oncology.

• JC-1 Mitochondrial Membrane Potential Assay Kit: Applied Wor

  2026-07-31

  The JC-1 Mitochondrial Membrane Potential Assay Kit stands out for sensitive, quantitative mitochondrial membrane potential analysis across apoptosis and immunometabolic research. This article unpacks its robust workflows, direct links to immunomodulatory research, and data-driven troubleshooting to support next-generation experimental design.

• Targeted PAD4 Inhibitors Disrupt Tumor Metastasis via Neutro

  2026-07-30

  This study presents a new class of phenylboronic acid (PBA)-modified PAD4 inhibitors that selectively target neutrophil PAD4 to suppress tumor growth and metastasis. By elucidating the PAD4-H3cit-NETs pathway, the research outlines a mechanism for high tumor specificity and reduced systemic toxicity, offering a promising strategy for anti-metastatic cancer therapy.

• Gingerenone A Restores Sunitinib Sensitivity in RCC via LDHA

  2026-07-30

  This study demonstrates that gingerenone A targets LDHA-mediated glycolysis to reverse sunitinib resistance in renal cell carcinoma models. The mechanistic findings highlight metabolic reprogramming as a key vulnerability in RCC, enabling potential adjuvant strategies for drug-resistant tumors.

• TRIM21 Drives Pituitary Adenoma Resistance: Quisinostat as a

  2026-07-29

  This study uncovers how TRIM21 enhances pituitary adenoma proliferation and drug resistance by promoting ERK1/2 ubiquitination and phosphorylation. It identifies Quisinostat as an effective HDAC inhibitor for reducing TRIM21 levels, offering a new strategy to overcome therapeutic resistance in these tumors.

14689 records 1/980 page Next 12345 下5页 Last page